Julie Netherland

Summary

Affiliation: New York Academy of Medicine
Country: USA

Publications

  1. pmc Factors affecting willingness to provide buprenorphine treatment
    Julie Netherland
    The New York Academy of Medicine, Division of Health Policy, New York, NY 10029, USA
    J Subst Abuse Treat 36:244-51. 2009
  2. pmc The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 56:S76-82. 2011
  3. doi Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care
    James E Egan
    The New York Academy of Medicine, Center for Evaluation and Applied Research, 1216 5th Avenue, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S46-53. 2011
  4. doi Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative
    Linda Weiss
    The New York Academy of Medicine, Center for Evaluation and Applied Research, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S68-75. 2011
  5. doi The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment
    Linda Weiss
    The New York Academy of Medicine, Center for Evaluation and Applied Research, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S7-13. 2011
  6. pmc The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment
    James E Egan
    New York Academy of Medicine, 1216 5th Avenue, New York, NY 10029, USA
    J Gen Intern Med 25:936-41. 2010
  7. doi Policy implications of integrating buprenorphine/naloxone treatment and HIV care
    Ruth Finkelstein
    The New York Academy of Medicine, Division of Health Policy, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S98-S104. 2011
  8. pmc A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center
    Linda Weiss
    Office of Special Populations, New York Academy of Medicine, 1216 Fifth Avenue, New York, NY 10029, USA
    J Urban Health 79:392-403. 2002
  9. doi Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY, USA
    AIDS Care 21:992-9. 2009
  10. ncbi Adherence to HAART: perspectives from clients in treatment support programs
    Linda Weiss
    Office of Special Populations, The New York Academy of Medicine, New York, NY 10029, USA
    Psychol Health Med 11:155-70. 2006

Detail Information

Publications10

  1. pmc Factors affecting willingness to provide buprenorphine treatment
    Julie Netherland
    The New York Academy of Medicine, Division of Health Policy, New York, NY 10029, USA
    J Subst Abuse Treat 36:244-51. 2009
    ..These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine...
  2. pmc The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 56:S76-82. 2011
    ..Implementing integrated HIV and buprenorphine/naloxone treatment requires cost estimates to plan and obtain funding...
  3. doi Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care
    James E Egan
    The New York Academy of Medicine, Center for Evaluation and Applied Research, 1216 5th Avenue, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S46-53. 2011
    ..Research has shown that buprenorphine/naloxone (bup/nx) is a safe and effective treatment for opioid dependence. Few reports, however, describe the patient perspective on bup/nx treatment and its integration into HIV care settings...
  4. doi Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative
    Linda Weiss
    The New York Academy of Medicine, Center for Evaluation and Applied Research, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S68-75. 2011
    ..The experiences of physicians leading the Buprenorphine HIV Evaluation and Support initiative provides valuable information for other HIV providers seeking to integrate medication-assisted treatment services into HIV clinical care...
  5. doi The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment
    Linda Weiss
    The New York Academy of Medicine, Center for Evaluation and Applied Research, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S7-13. 2011
    ..Although limitations to evaluation findings persist, they may be balanced by the scope and "real-world" context of the initiative...
  6. pmc The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment
    James E Egan
    New York Academy of Medicine, 1216 5th Avenue, New York, NY 10029, USA
    J Gen Intern Med 25:936-41. 2010
    ..The PCSS-B model provides support for a mentorship program to assist non-specialty physicians in the provision of buprenorphine and may serve as a model for dissemination of other types of care...
  7. doi Policy implications of integrating buprenorphine/naloxone treatment and HIV care
    Ruth Finkelstein
    The New York Academy of Medicine, Division of Health Policy, New York, NY 10029, USA
    J Acquir Immune Defic Syndr 56:S98-S104. 2011
    ..By addressing some of the policy barriers to integration, this promising new treatment can help the thousands of people living with HIV/AIDS who are also opioid dependent...
  8. pmc A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center
    Linda Weiss
    Office of Special Populations, New York Academy of Medicine, 1216 Fifth Avenue, New York, NY 10029, USA
    J Urban Health 79:392-403. 2002
    ..Other participants were essentially forced to limit use by marked reductions in income. For others, access to health and social service professionals, as well as drug treatment, proved to be key...
  9. doi Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY, USA
    AIDS Care 21:992-9. 2009
    ..ACASI screening should be considered in HIV clinical care settings to assist providers in identifying patients with the greatest need for targeted psychosocial services including adherence support and depression care...
  10. ncbi Adherence to HAART: perspectives from clients in treatment support programs
    Linda Weiss
    Office of Special Populations, The New York Academy of Medicine, New York, NY 10029, USA
    Psychol Health Med 11:155-70. 2006
    ..Educational, practical, and supportive services were all considered valuable to clients participating in adherence support programs. A mix of services may best meet the range of needs found among persons taking HAART...